TEVA — TEVA PHARMACEUTICAL INDUSTRIES LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 818686 ·
Israel
Last close
$39.19
Market Cap
$45.67B
52W High
$40.79
52W Low
$18.27
ADV30
4,984,570
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 3,981,000,000 | 1,972,000,000 | 759,000,000 | 369,000,000 | 40,040,000,000 | 3,741,000,000 | 31,808,000,000 |
| Dec 2025 | 4,711,000,000 | 2,656,000,000 | 1,269,000,000 | 480,000,000 | 40,748,000,000 | 3,556,000,000 | 32,834,000,000 |
| Sep 2025 | 4,480,000,000 | 2,304,000,000 | 1,075,000,000 | 433,000,000 | 39,856,000,000 | 2,203,000,000 | 32,602,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,898,000,000
Investing CF
$39,000,000
Financing CF
$-401,000,000
CapEx
$-550,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.60
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-13,969,000,000
Inventory
$3,221,000,000
Receivables
$3,493,000,000
ST Investments
—
EBIT TTM
$1,605,000,000
Pretax Income TTM
$708,000,000
Interest Exp TTM
$897,000,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,315,000,320
EBITDA
$4,268,000,000
Free Cash Flow
$2,219,875,072
Enterprise Value
$56,463,831,040
Total Cash
$3,655,000,064
Total Debt
$16,894,000,128
Shares Out
1,165,296,084
Trailing EPS
$0.60
Book Value
$6.65
ROE
9.7%
ROA
5.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 17,257,000,000 | 3,952,000,000 | 1,410,000,000 | 40,748,000,000 | 32,834,000,000 | 7,910,000,000 | 1,649,000,000 |
| Dec 2024 | 16,544,000,000 | 3,364,000,000 | -1,639,000,000 | 39,326,000,000 | 33,606,000,000 | 5,373,000,000 | 1,247,000,000 |
| Dec 2023 | 15,845,000,000 | 3,194,000,000 | -559,000,000 | 43,479,000,000 | 35,353,000,000 | 7,506,000,000 | 1,368,000,000 |
| Dec 2022 | 14,925,000,000 | 2,690,000,000 | -2,446,000,000 | 44,011,000,000 | 35,413,000,000 | 7,804,000,000 | 1,590,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.07
Max Pain — expiry 2026-10-16
max pain strike: $37.00 · spot: $38.97 · call oi: 14,055 · put oi: 9,834
Expected Move to 2026-10-16:
±$2.26
(5.80%) —
implied range
$36.71 –
$41.23
· ATM straddle on $39.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ONC | BeOne Medicines Ltd. | $37.63B | $360.85 | — |
| TAK | TAKEDA PHARMACEUTICAL CO LTD | $60.23B | $18.86 | — |
| ALNY | ALNYLAM PHARMACEUTICALS, INC. | $34.25B | $255.96 | — |
| ZTS | Zoetis Inc. | $29.36B | $71.05 | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $79.70B | $788.04 | — |
News headlines (Yahoo Finance, 1h cache)
Teva Releases Q3 2026 Aide Memoire
2026-09-23 20:45 · Yahoo
Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
2026-09-23 20:45 · Yahoo
Teva Enters Acceleration Phase of Transformation Supported by Multi-Year Launch Cycle, Oppenheimer Says
2026-09-23 16:13 · Yahoo
Teva Eyes New Growth Phase After Securing Investment-Grade Ratings
2026-09-23 12:02 · Yahoo
Teva CEO Details Biopharma Pivot, $700M Savings Plan and Growth Pipeline
2026-09-22 09:02 · Yahoo
Teva Pharmaceutical Industries (TEVA), Why Is It Back In The Spotlight?
2026-09-21 19:11 · Yahoo
Medincell's Partner Teva Presented New Data on Investigational Olanzapine LAI and UZEDY® at Psych Congress 2026
2026-09-21 06:00 · Yahoo
Remepy Welcomes Pharma R&D Leader, Eran Harary, MD, as Chief Medical Officer, to Advance Hybrid Drug™ Pipeline
2026-09-16 11:30 · Yahoo
Teva Says Pivot to Growth Gains Steam as Branded Drugs, Biosimilars Outperform
2026-09-15 00:02 · Yahoo
Teva CEO on the company’s NYSE debut and what's next
2026-09-14 20:39 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.